Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 study of Renzapride in patients with diabetic gastroparesis

Next Previous
X
Search
Trial Profile

Phase 2 study of Renzapride in patients with diabetic gastroparesis

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2017

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Renzapride (Primary)
  • Indications Diabetic gastroparesis
  • Focus Registrational; Therapeutic Use
  • Sponsors EndoLogic

    • Most Recent Events

    • 09 Aug 2017 According to an EndoLogic media release, company anticipate submitting the IND in the fourth quarter of 2017, with dosing of the first patient expected in the second quarter of 2018.
    • 09 Aug 2017 According to an EndoLogic media release, if successful, this study will be considered as one of two pivotal trials essential to submit an NDA.
    • 03 May 2017 According to an EndoLogic media release, the FDA has scheduled a pre-IND meeting with EndoLogic to discuss the requirements for this proposed phase II study. The meeting will be on July 25, 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top